Skip to main content
Download PDF
- Main
Baricitinib Treatment of Coronavirus Disease 2019 Is Associated With a Reduction in Secondary Infections
- Sweeney, Daniel A;
- Tuyishimire, Bonifride;
- Ahuja, Neera;
- Beigel, John H;
- Beresnev, Tatiana;
- Cantos, Valeria D;
- Castro, Jose G;
- Cohen, Stuart H;
- Cross, Kaitlyn;
- Dodd, Lori E;
- Erdmann, Nathan;
- Fung, Monica;
- Ghazaryan, Varduhi;
- George, Sarah L;
- Grimes, Kevin A;
- Hynes, Noreen A;
- Julian, Kathleen G;
- Kandiah, Sheetal;
- Kim, Hannah Jang;
- Levine, Corri B;
- Lindholm, David A;
- Lye, David C;
- Maves, Ryan C;
- Oh, Myoung-Don;
- Paules, Catharine;
- Rapaka, Rekha R;
- Short, Willam R;
- Tomashek, Kay M;
- Wolfe, Cameron R;
- Kalil, Andre C
- et al.
Published Web Location
https://doi.org/10.1093/ofid/ofad205Abstract
We performed a secondary analysis of the National Institutes of Health-sponsored Adaptive COVID-19 Treatment Trial (ACTT-2) randomized controlled trial and found that baricitinib was associated with a 50% reduction in secondary infections after controlling for baseline and postrandomization patient characteristics. This finding provides a novel mechanism of benefit for baricitinib and supports the safety profile of this immunomodulator for the treatment of coronavirus disease 2019.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.
Main Content
For improved accessibility of PDF content, download the file to your device.
Enter the password to open this PDF file:
File name:
-
File size:
-
Title:
-
Author:
-
Subject:
-
Keywords:
-
Creation Date:
-
Modification Date:
-
Creator:
-
PDF Producer:
-
PDF Version:
-
Page Count:
-
Page Size:
-
Fast Web View:
-
Preparing document for printing…
0%